FDA Releases SUPAC Guidance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Releases SUPAC Guidance


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has released a draft guidance of scale-up and post-approval changes that combines and supersedes previous guidance documents: SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum and SUPAC-SS Nonsterile Semisolid Dosage Forms, Manufacturing Equipment Addendum. FDA states that the new draft SUPAC addendum should be used in combination with the other SUPAC guidance documents.

This draft guidance, Guidance for Industry SUPAC: Manufacturing Equipment Addendum, Draft Guidance, removes the lists of manufacturing equipment that were in the previous guidance documents and clarifies the types of processes being referenced. It defines levels of chemistry, manufacturing, and control change; recommended chemistry, manufacturing, and controls tests for each level of change; recommended in vitro dissolution and release tests and/or in vivo bioequivalence tests for each level of change; and recommended documentation that should support the change for new drug applications and abbreviated new drug applications.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here